CoChat
Sign Up
Cited by 408

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression

Teng, Yun, Ren, Yi, Hu, Xin, Mu, Jingyao, Samykutty, Abhilash, Zhuang, Xiaoying, Deng, Zhongbin, Kumar, Anil, Zhang, Lifeng, Merchant, Michael L., Yan, Jun, Miller, Donald M., Zhang, Huang-Ge·2017·Nature Communications
DOI 10.1038/ncomms14448
Open this paper in CoChat — free account

Abstract

Exosomes are emerging mediators of intercellular communication; whether the release of exosomes has an effect on the exosome donor cells in addition to the recipient cells has not been investigated to any extent. Here, we examine different exosomal miRNA expression profiles in primary mouse colon tumour, liver metastasis of colon cancer and naive colon tissues. In more advanced disease, higher levels of tumour suppressor miRNAs are encapsulated in the exosomes. miR-193a interacts with major vault protein (MVP). Knockout of MVP leads to miR-193a accumulation in the exosomal donor cells instead of exosomes, inhibiting tumour progression. Furthermore, miR-193a causes cell cycle G1 arrest and cell proliferation repression through targeting of Caprin1, which upregulates Ccnd2 and c-Myc. Human colon cancer patients with more advanced disease show higher levels of circulating exosomal miR-193a. In summary, our data demonstrate that MVP-mediated selective sorting of tumour suppressor miRNA into exosomes promotes tumour progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms14448

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 49

  1. Au Yeung, C. L. et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat. Commun. 7, 11150 (2016). · DOI
  2. Deng, Z. et al. Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nat. Commun. 6, 6956 (2015). · DOI
  3. Zhang, L. et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527, 100–104 (2015). · DOI · Paper page
  4. Tkach, M. & Thery, C. Communication by extracellular vesicles: where we are and where we need to go. Cell 164, 1226–1232 (2016). · DOI · Paper page
  5. Thery, C. Cancer: diagnosis by extracellular vesicles. Nature 523, 161–162 (2015). · DOI
  6. Bobrie, A. & Thery, C. Exosomes and communication between tumours and the immune system: are all exosomes equal? Biochem. Soc. Trans. 41, 263–267 (2013). · DOI
  7. Bobrie, A., Colombo, M., Krumeich, S., Raposo, G. & Thery, C. Diverse subpopulations of vesicles secreted by different intracellular mechanisms are present in exosome preparations obtained by differential ultracentrifugation. J. extracell. vesicles 1, 18397 (2012). · DOI
  8. Thery, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nat. rev. Immunol. 9, 581–593 (2009). · DOI
  9. Peinado, H. et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. med. 18, 883–891 (2012). · DOI · Paper page
  10. Bobrie, A. et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer res. 72, 4920–4930 (2012). · DOI
  11. Trajkovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244–1247 (2008). · DOI
  12. Lai, C. P., Tannous, B. A. & Breakefield, X. O. Noninvasive in vivo monitoring of extracellular vesicles. Meth. mol. biol. 1098, 249–258 (2014). · DOI
  13. Zomer, A. et al. Exosomes: fit to deliver small RNA. Commun. integr. biol. 3, 447–450 (2010). · DOI
  14. Ridder, K. et al. Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. Oncoimmunology 4, e1008371 (2015). · DOI
  15. Lai, C. P. et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS nano 8, 483–494 (2014). · DOI
  16. Hannafon, B. N. et al. Plasma exosome microRNAs are indicative of breast cancer. Breast cancer res. 18, 90 (2016). · DOI
  17. Zoller, M. Exosomes in cancer disease. Meth. mol. biol. 1381, 111–149 (2016). · DOI
  18. Laurent, L. C. et al. Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. J. extracell. vesicles 4, 26533 (2015). · DOI
  19. Hornick, N. I. et al. Serum exosome microRNA as a minimally-invasive early biomarker of AML. Sci. rep. 5, 11295 (2015). · DOI
  20. Shao, H. et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat. commun. 6, 6999 (2015). · DOI
  21. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. cell biol. 10, 1470–1476 (2008). · DOI · Paper page
  22. Teng, Y. et al. Grapefruit-derived nanovectors deliver miR-18a for treatment of liver metastasis of colon cancer by induction of M1 macrophages. Oncotarget 7, 25683–25697 (2016). · DOI
  23. Thind, A. & Wilson, C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. J. extracell. vesicles 5, 31292 (2016). · DOI
  24. Munagala, R., Aqil, F. & Gupta, R. C. Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour biol. 37, 10703–10714 (2016). · DOI
  25. Shi, R. et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget 6, 26971–26981 (2015). · DOI
  26. Chiam, K. et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J. gastrointest. surg. 19, 1208–1215 (2015). · DOI
  27. Warnecke-Eberz, U., Chon, S. H., Holscher, A. H., Drebber, U. & Bollschweiler, E. Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor. Tumour biol. 36, 4643–4653 (2015). · DOI
  28. Gajos-Michniewicz, A., Duechler, M. & Czyz, M. MiRNA in melanoma-derived exosomes. Cancer lett. 347, 29–37 (2014). · DOI
  29. Aushev, V. N. et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS ONE 8, e78649 (2013). · DOI
  30. Camacho, L., Guerrero, P. & Marchetti, D. MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS ONE 8, e73790 (2013). · DOI
  31. Chugh, P. E. et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS pathog. 9, e1003484 (2013). · DOI
  32. Taylor, D. D. & Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. oncol. 110, 13–21 (2008). · DOI
  33. Colombo, M., Raposo, G. & Thery, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Ann. rev. cell dev. biol. 30, 255–289 (2014). · DOI · Paper page
  34. Witwer, K. W. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. extracell. vesicles 2, 20360 (2013). · DOI
  35. Zhao, Y. N., He, D. N., Wang, Y. D., Li, J. J. & Ha, M. W. Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. Oncol. lett. 11, 2925–2933 (2016). · DOI
  36. Balan, S. et al. Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis. Gene 526, 449–453 (2013). · DOI
  37. Lu, C. & Shervington, A. Chemoresistance in gliomas. Mol. cell. biochem. 312, 71–80 (2008). · DOI
  38. Yan, X. D., Li, M., Yuan, Y., Mao, N. & Pan, L. Y. Biological comparison of ovarian cancer resistant cell lines to cisplatin and taxol by two different administrations. Oncol. rep. 17, 1163–1169 (2007).
  39. Sisodiya, S. M. et al. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol. appl. neurobiol. 32, 51–63 (2006). · DOI
  40. Yi, C. et al. Major vault protein, in concert with constitutively photomorphogenic 1, negatively regulates c-Jun-mediated activator protein 1 transcription in mammalian cells. Cancer res. 65, 5835–5840 (2005). · DOI
  41. Kolli, S., Zito, C. I., Mossink, M. H., Wiemer, E. A. & Bennett, A. M. The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J. biol. chem. 279, 29374–29385 (2004). · DOI · Paper page
  42. Mossink, M. H., van Zon, A., Scheper, R. J., Sonneveld, P. & Wiemer, E. A. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22, 7458–7467 (2003). · DOI
  43. Wu, Y., Zhu, J., Huang, X. & Du, Z. Crystal structure of a dimerization domain of human Caprin-1: insights into the assembly of an evolutionarily conserved ribonucleoprotein complex consisting of Caprin-1, FMRP and G3BP1. Acta Crystallogr. D Struct. Biol. 72, 718–727 (2016). · DOI
  44. Qiu, Y. Q. et al. Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget. Oncotarget 6, 2148–2163 (2015). · DOI
  45. Solomon, S. et al. Distinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRNAs. Mol. cell. biol. 27, 2324–2342 (2007). · DOI
  46. Ostrowski, M. et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. cell biol. 12, 19–30 sup. 1–13 (2010). · DOI
  47. Pu, Y. et al. MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively. Clin. exp. metastasis 33, 359–372 (2016). · DOI
  48. Xiang, X. et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 30, 3440–3453 (2011). · DOI
  49. Liu, Y. et al. COP9-associated CSN5 regulates exosomal protein deubiquitination and sorting. Am. j. pathol. 174, 1415–1425 (2009). · DOI

Cited by

Sorted by citations

See all 408

Metadata

Authors
Teng, Y., Ren, Y., Hu, X., Mu, J., Samykutty, A., Zhuang, X., Deng, Z., Kumar, A., Zhang, L., Merchant, M. L., Yan, J., Miller, D. M., & Zhang, H.-G.
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2017-02-17
Volume
8
Issue
1
ISSN
2041-1723
DOI
10.1038/ncomms14448
Cited by
408
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review